# CanSino Biologics

continues advancing its proprietary mRNA vaccine platform, reporting Phase II safety and immunogenicity data for its CS-2034 mRNA vaccine in Chinese adults, building on its earlier position as a global pioneer of adenoviral-vector vaccines.

Source: https://en.bioecon.ru/companies/cansino/
Updated: 2026-07-05

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | RMB 1,059.4 million (2025-12-31) | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033003432.pdf |
| Capacity | 100 million doses per year for mRNA facility in Shanghai (2023-02-20) | http://cansinotech.com/detail-3942 |
| Production site | Tianjin and Shanghai, China; additional lines in Mexico, Pakistan, and Malaysia (2023-12-31) | https://cansinotech.com/uploadfile/HE/1716444608006.pdf |
| Certification | GMP certificate from Malaysian NAPRA for meningococcal and pneumococcal vaccine facility (2026-03-30) | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033003432.pdf |
| Certification | Halal certification in Indonesia for Menhycia vaccine (2025-03-28) | https://www.cansinotech.com/detail-4484 |

Independent sources: hkexnews.hk

## Technologies

- [Drug & vaccine development](https://en.bioecon.ru/technology/drug-vaccine-development/)